Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent
The Mayo genetic risk models offer pre-treatment and response-based prognostic tools for newly diagnosed AML treated with Ven-HMA.
Related Articles
Nico Gagelmann: Clearance of driver mutations after transplantation for myelofibrosis – OncoDaily
Nico Gagelmann: Clearance of driver mutations after transplantation for myelofibrosis / Anita Badbaran, Boris Fehse, cancer, Carolina Berger, Catherina Lück,
Integrating artificial intelligence with mechanistic epidemiological modeling: a scoping review of opportunities and challenges
Nature Communications – Artificial intelligence has the potential to improve epidemiological models of infectious diseases by incorporating diverse data sources and complex interactions. Here, the…
Minimum Levels of Stress
A day after the September 11th terrorist attacks, every member of Congress stood on the steps of the U.S.
Multi-Gene Panel for Thrombophilia Testing in Venous Thromboembolism
Conventional tests for inherited thrombophilia focus on the five most-established inherited thrombophilias; i.e. deficiencies in antithrombin, protein C, and protein S, and the factor V…
Has ‘Patient Centeredness’ Gone Too Far?
Patient centeredness is not a reason to accede to misguided medical decisions, argues Jack West.
Adobe Acrobat – div-class-title-industry-funding-by-itself-is-not-a-reason-for-rating-down-studies-for-risk-of-bias-div.pdf
View this file, and add comments too.
Myeloma Paper of the Day, January 13th, suggested by Robert Orlowski – OncoDaily
Myeloma Paper of the Day, January 13th, suggested by Robert Orlowski / Andrew Spencer, Anna Kalff, Antonia Reale, Blood Cancer Journal, BRAF, cancer, Daniel
‘Modern Love’ Podcast: Finding the Magic, Just in Time
Clare Cory was 59 years old and had been single almost her whole life. She thought her love story was over. Then everything changed.
